view continu like data
see high likelihood demonstr benefit vs soliri
soliri guidanc came light vs expect view take
clear backseat data year dictat futur growth
trajectori compani
model chang updat model reflect
financi result updat forecast base oper
product guidanc soliri model vs
prior metabol franchis model vs
prior total revenu gaap/non-gaap
model sg
model oper margin
model gaap/non-gaap tax rate
model gaap/non-gaap ep
model pleas see first take analysi
quarter guidanc
valu come clinic de-risk vs soliri
growth model soliri sale pnh ahu nearli flat
clinic trial headwind growth launch gmg headwind
clinic trial recruit pnh competitor
well unfavor price dynam eu latam drive
global declin ww pnh ahu soliri sale est call management
guid y/i headwind due trial recruit
expect top forecast soliri
commerci pnh share declin q/q larg us
eu due competitor trial activ addit forecast price declin
eu row reflect price headwind guid
howev see potenti soliri launch mg approv
us eu jp larg off-set forecast
mg sale model reflect commercial/onboard patient ramp
guid date us market treatment
earli jan grow earli feb provid basi
estim treat averag quarter
end quarter model us sale eu
sale apac sale reflect jp launch total soliri
revenu forecast ww sale
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
rate outperform pt base
sum-of-the-part sotp methodolog estim
probability-adjust npv follow soliri sale pnh
soliri sale ahu strensiq
sale kanuma sale lal-d
soliri sale mg soliri sale nmo
share compani project cash
posit compani debt posit
price target support outperform rate
upsid scenario assum posit data
read-out soliri studi nmo faster
expect uptak metabol franchis
clinic success studi pnh
downsid scenario assum neg
readout soliri studi nmo neg readout
studi pnh ahu case
assum stock trade base valu
establish soliri busi metabol franchis
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow management
could help protect pnh ahu market
competitor see dose regimen
promis highli conveni though riski development
strategi present pk dose
use remain unclear whether
recycl strategi use extend half life
hold high concentr note therapeut
antibodi commerci high dose
though conced dose would like seen
conveni mani competitor develop daily/
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip issuanc
similar patent eu extend protect
eu countri view biosimilar soliri near term
upcom potenti catalyst updat
studi dec dec result
pnh studi naiv pt result
soliri prevent studi nmo initi
subq studi late
risk factor neg influenc valuat
rate includ neg readout soliri nmo studi
studi pnh ahu posit develop
progress competitor complement program
compani report capit market estim
compani report capit market estim
soliri pnh ahu lal-d mg nmo pnh ahu mg nmo valu stock dilut share outstand net market sum-of-the-part valuat
rate outperform pt base sum-of-the-part sotp
methodolog estim probability-adjust npv follow soliri sale pnh
soliri sale ahu strensiq sale
kanuma sale lal-d soliri sale mg soliri sale nmo
compani project cash posit
compani debt posit price target support outperform rate
risk rate price target
factor neg influenc valuat rate includ neg readout
soliri nmo studi develop set-back includ neg readout
studi pnh ahu posit develop progress competitor complement
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
